Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
2024-09-25 7:14 pm Purchase | 13G | ACHILLES THERAPEUTICS PLC ACHL | BML Investment Partners L.P. | 4,100,002 9.970% | 4,100,002 (New Position) | View |
2024-03-29 4:30 pm Sale | 13G | ACHILLES THERAPEUTICS PLC ACHL | Artal International S.C.A. | 755,375 1.900% | -1,500,000 (-66.51%) | View |
2024-02-14 4:21 pm Sale | 13G | ACHILLES THERAPEUTICS PLC ACHL | BAKER BROS. ADVISORS LP | 3,311,567 8.100% | -896,166 (-21.30%) | View |
2024-02-13 6:40 pm Unchanged | 13G | ACHILLES THERAPEUTICS PLC ACHL | Syncona Portfolio Ltd | 11,086,909 27.200% | 0 (Unchanged) | View |
2023-02-14 4:29 pm Sale | 13G | ACHILLES THERAPEUTICS PLC ACHL | Redmile Group LLC | 1,608,089 3.900% | -480,000 (-22.99%) | View |
2023-02-14 4:00 pm Purchase | 13G | ACHILLES THERAPEUTICS PLC ACHL | BAKER BROS. ADVISORS LP | 4,207,733 9.900% | 168,253 (+4.17%) | View |
2023-02-14 4:00 pm Sale | 13G | ACHILLES THERAPEUTICS PLC ACHL | Point72 Asset Management L.P. | 1,413,809 3.600% | -667,241 (-32.06%) | View |
2023-02-10 7:15 pm Unchanged | 13G | ACHILLES THERAPEUTICS PLC ACHL | Artal International S.C.A. | 2,255,375 5.500% | 0 (Unchanged) | View |
2022-12-30 4:57 pm Sale | 13D | ACHILLES THERAPEUTICS PLC ACHL | RA CAPITAL MANAGEMENT L.P. | 1,607,834 13.000% | -1,369,109 (-45.99%) | View |
2022-12-23 5:15 pm Sale | 13D | ACHILLES THERAPEUTICS PLC ACHL | RA CAPITAL MANAGEMENT L.P. | 2,976,943 13.000% | -1,130,565 (-27.52%) | View |
2022-12-15 5:01 pm Sale | 13D | ACHILLES THERAPEUTICS PLC ACHL | RA CAPITAL MANAGEMENT L.P. | 4,107,508 13.000% | -907,179 (-18.09%) | View |
2022-07-25 5:20 pm Purchase | 13G | ACHILLES THERAPEUTICS PLC ACHL | Point72 Asset Management L.P. | 2,081,050 5.300% | 2,081,050 (New Position) | View |
2022-02-14 5:07 pm Purchase | 13G | ACHILLES THERAPEUTICS PLC ACHL | Redmile Group LLC | 2,088,089 5.100% | 2,088,089 (New Position) | View |
2022-02-14 4:12 pm Purchase | 13G | ACHILLES THERAPEUTICS PLC ACHL | BAKER BROS. ADVISORS LP | 4,039,480 9.990% | 4,039,480 (New Position) | View |
2022-02-11 12:22 pm Purchase | 13G | ACHILLES THERAPEUTICS PLC ACHL | Syncona Portfolio Ltd | 11,086,909 27.300% | 11,086,909 (New Position) | View |
2022-02-11 09:20 am Purchase | 13G | ACHILLES THERAPEUTICS PLC ACHL | Forbion Capital Fund IV Cooperatief U.A. | 2,390,050 5.890% | 2,390,050 (New Position) | View |
2021-04-16 4:34 pm Purchase | 13D | ACHILLES THERAPEUTICS PLC ACHL | RA CAPITAL MANAGEMENT L.P. | 5,014,687 12.340% | 5,014,687 (New Position) | View |
2021-04-15 5:02 pm Purchase | 13G | ACHILLES THERAPEUTICS PLC ACHL | Artal International S.C.A. | 2,255,375 5.600% | 2,255,375 (New Position) | View |